Sesquiterpenoids with anti-neuroinflammatory effects in vitro from Laggera alata

IF 1.7 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2026-04-01 Epub Date: 2026-01-15 DOI:10.1016/j.phytol.2026.104114

Xingxi Li, Wenhao Qiao, Qian Yang, Mingzhu Hu, Enhui Wang, Rongping Zhang, Xinglong Chen

{"title":"Sesquiterpenoids with anti-neuroinflammatory effects in vitro from Laggera alata","authors":"Xingxi Li, Wenhao Qiao, Qian Yang, Mingzhu Hu, Enhui Wang, Rongping Zhang, Xinglong Chen","doi":"10.1016/j.phytol.2026.104114","DOIUrl":null,"url":null,"abstract":"<div><div>A total of four sesquiterpenoids were isolated and identified from Laggera alata. Compounds 1 and 2 were previously undescribed compounds. The absolute configuration of compounds 3 and 4 were deduced for the first time. The new compounds were characterized using HRESIMS NMR, and ECD methods. They were (2S,4 R,5S,7S)-3-methoxy-arimophane-1(10),11(13)-diene-12-acid (1) and (7S,10S)-eudesmane-4,11(13)-diene-3-one-12-acid (2). All compounds were evaluated for their anti-neuroinflammatory activities on LPS-induced BV2 cells. Compound 2 exhibited significant anti-neuroinflammatory activity at concentrations of 10, 20, and 40 μM. Only compounds 1, 3, and 4 showed anti-neuroinflammatory activity at a concentration of 40 μM. These results confirm that L. alata contains sesquiterpenoids, which demonstrate potential anti-neuroinflammatory properties, thereby establishing a pharmacological foundation for combating neuroinflammation.</div></div>","PeriodicalId":20408,"journal":{"name":"Phytochemistry Letters","volume":"72 ","pages":"Article 104114"},"PeriodicalIF":1.7000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytochemistry Letters","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1874390026000042","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

A total of four sesquiterpenoids were isolated and identified from Laggera alata. Compounds 1 and 2 were previously undescribed compounds. The absolute configuration of compounds 3 and 4 were deduced for the first time. The new compounds were characterized using HRESIMS NMR, and ECD methods. They were (2S,4 R,5S,7S)-3-methoxy-arimophane-1(10),11(13)-diene-12-acid (1) and (7S,10S)-eudesmane-4,11(13)-diene-3-one-12-acid (2). All compounds were evaluated for their anti-neuroinflammatory activities on LPS-induced BV2 cells. Compound 2 exhibited significant anti-neuroinflammatory activity at concentrations of 10, 20, and 40 μM. Only compounds 1, 3, and 4 showed anti-neuroinflammatory activity at a concentration of 40 μM. These results confirm that L. alata contains sesquiterpenoids, which demonstrate potential anti-neuroinflammatory properties, thereby establishing a pharmacological foundation for combating neuroinflammation.

查看原文本刊更多论文

龙葵倍半萜类体外抗神经炎作用

从龙葵中分离鉴定了4个倍半萜类化合物。化合物1和2是之前未被描述的化合物。首次推导出化合物3和4的绝对构型。新化合物通过HRESIMS NMR和ECD方法进行了表征。分别为（2S,4 R,5S,7S）-3-甲氧基-芳胺芬-1(10),11(13)-二烯-12-酸(1)和(7S,10S)-枫烯-4,11(13)-二烯-3- 1 -12-酸(2)。所有化合物对lps诱导的BV2细胞的抗神经炎活性进行了评估。化合物2在浓度为10、20和40 μM时表现出显著的抗神经炎活性。只有化合物1、3和4在浓度为40 μM时表现出抗神经炎活性。这些结果证实了雪莲含有倍半萜类化合物，具有潜在的抗神经炎症特性，从而为抗神经炎症奠定了药理学基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.